logo
The Ultra Wealthy Are Riding Out the Market Chaos in Luxury Real Estate

The Ultra Wealthy Are Riding Out the Market Chaos in Luxury Real Estate

A year ago, entrepreneur Dan Herbatschek was just another New Yorker hunting for a larger apartment for his family. But since March, he has signed contracts to buy four Manhattan condos despite the economic turmoil spurred by global tariffs. Now Herbatschek is part of another group: affluent buyers investing in ultraluxury real estate amid the uncertainty.
'The chance of taking a hit in the stock market is a bit too high for the reward, especially when we consider inflation,' said Herbatschek, an applied mathematician and tech-company founder. 'Real estate is safer, less volatile.'
In early May, he signed a $12.25 million contract on a five-bedroom Upper East Side condo for himself, his wife and three children. He is also buying three investment properties priced between $2 million and roughly $5.5 million. 'We've deployed more than $20 million so far,' said Wendy Chang Lee of Douglas Elliman, Herbatschek's real-estate agent.
Herbatschek's thinking is far from unusual. Despite a chill in the overall housing market, ultraluxury home sales in areas like New York, South Florida and Los Angeles are accelerating as the wealthy buyers bet on real estate's long-term value. Since February, the number of homes sold for $10 million or more has surged in major markets nationwide, according to an exclusive analysis by The Wall Street Journal. Between Feb. 1 and May 1, sales at that price point in Palm Beach, Fla., surged 50% from the same period last year, while sales in Miami-Dade County jumped 48.5% year-over-year, according to public records and local multiple listing service data. In the luxury ski destination of Aspen, Colo., sales jumped 43.75% in that same period, followed by Los Angeles County at 29% and Manhattan at 21%.
Palm Beach real-estate agent Dana Koch of the Corcoran Group, who has brokered two roughly $50 million deals in the last month, said buyers are turning to real estate because it's a tangible asset. 'It's just a safe place to put your money to ride out this wave and see what transpires,' he said.
When President Trump's tariffs were first announced, some wealthy buyers tapped the brakes and backed out of deals. In recent weeks, however, real-estate observers have been surprised to see a wave of big-ticket sales across the country.
The largest was the $225 million sale of a residential compound in Naples, Fla., in late April, the country's second-most expensive home sale ever recorded. The seller was tied to the DeGroote family of Canada, property records show. The same week, billionaire David Hoffmann paid $85 million for a waterfront property nearby.
In Los Angeles, Australian billionaire James Packer paid $110 million for a lavish mansion, while in the San Francisco Bay Area, an Atherton mansion sold in April for $51.5 million, one of the highest prices ever recorded in the area. In New York, British property developer Christian Candy and his wife, Emily Crompton-Candy, paid $46.9 million for a four-bedroom triplex at 111 West 57th Street, one of Midtown's new supertall condominiums. And hotelier Vladislav Doronin sold his home on Miami Beach's Star Island for $125 million in March.
'For my clients, it's business as usual,' said Coldwell Banker Realty agent Jade Mills, who is in the midst of negotiating a deal for more than $30 million in Beverly Hills, Calif. 'If anything, we're seeing people taking money out of the stock market at a loss and buying real estate.'
Palm Beach has seen a number of megadeals, including investor Andrew Farkas's $51.42 million sale to Bren Simon, the widow of Simon Property Group founder Mel Simon. Billionaire Red Ventures co-founder Ric Elias sold his waterfront mansion to real-estate investor Mark Paley for $73 million in March. That same month, billionaire manufacturing executive David MacNeil inked a contract to pay $55.5 million for property adjacent to a site he already owns in the nearby town of Manalapan. He has plans to raze a partially completed home on the site to make way for a new estate.
MacNeil would actually have been willing to pay up to $75 million for the site, he said in an email. 'The sellers obviously left the casino way too early. Lucky for me!' he quipped.
The deal will bring his total spend in Manalapan to roughly $94 million over the past year. 'There's really no bad time to buy great properties,' he said. 'No one ever regretted buying the very best, whether it is a premium collector car or a piece of premium real estate. Scared money chases bargains, and smart money chases excellence.'
Florida-based entrepreneur Todd Green closed May 8 on a slopeside vacation home in Vail, Colo., for $17.8 million after going into contract in April. The five-bedroom penthouse is substantially larger than one he already owned in the area. Green, who owns a string of car dealerships in Illinois and various other businesses, said he has a substantial amount of money in equities, but isn't worried about temporary swings in the market.
'It's like Warren Buffett always said: If you're thinking about the stock market over a period of a day or a week, you shouldn't be in it,' Green said. 'I don't plan on ever selling my stocks, so this is a little blip on the radar.'
A hit to the stock market doesn't take the same toll on a '$100 million guy' as it does on the merely wealthy, noted Chadd Ziegler of Christiania Realty in Vail, who represented Green in his purchase. 'That person doesn't need to sell their third home to buy Cheerios for breakfast the next morning.'
Home buyers at lower price points, by contrast, are holding off on buying and selling amid the chaos, agents said. For Miami homes below $20 million, for example, listing prices have dropped 10% to 20% since the start of the trade war, said agent Danny Hertzberg of Coldwell Banker.
'The most bullish buyers seem to be the highest-net worth buyers,' said Hertzberg, who knows of at least three Miami homes in contract to sell for $40 million or more. 'The rest of the market is soft—frozen in some aspects—whereas the top of the market is accelerating in the number of sales and prices.'
Many of Hertzberg's high-net-worth clients want to buy now because they think construction will become more expensive as the effect of the tariffs becomes clear, Hertzberg added.
Hoffmann, an activist investor, already owned a smaller home in Naples but was searching for a larger compound in the area for five years. 'This wasn't a spur of the moment thing,' he said. The $85 million house, which measures about 17,200 square feet with eight bedrooms, ticked all the boxes in terms of design, size, quality and location. He is also in contract to buy the adjacent property with a guesthouse, bringing the total purchase price to just over $100 million. The two properties had been listed for a combined $125 million.
Hoffmann said he has diverse investments, including a 'significant' amount of money in the stock market, but isn't worried about short-term fluctuations. Moreover, he felt he got a good deal on the Naples home, since it would cost about $110 million to build today.
'It sounds crazy to spend $85 million for a house and say it's a great value, but it was,' Hoffmann said.
For his part, MacNeil said he wasn't spooked by the tariffs or the stock market turmoil, in part because he is a supporter of Trump's trade policies.
'The President's tariffs are absolutely a good thing,' MacNeil said. 'People have to be patient with his plan and allow him to work his magic and soon the economy will be on fire.' He added a flame emoji.
Write to E.B. Solomont at eb.solomont@wsj.com and Katherine Clarke at Katherine.Clarke@wsj.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

Yahoo

time8 minutes ago

  • Yahoo

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe to meet potentially high commercial demand. Piramal Pharma Solutions harnessed the strength of two additional facilities to efficiently produce the FDC, demonstrating the advantages of its integrated approach to development. MUMBAI, India, Aug. 21, 2025 /CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), and NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) today announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA. As one of Piramal Pharma Solutions' focused drug product facilities, the Sellersville site provides comprehensive development and manufacturing services for various formulations, including several forms of OSDs. This addition will increase operational efficiency, helping NewAmsterdam Pharma to deliver its investigational drug therapy, if approved, to patients in need. The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities. This includes a reconfiguration of existing space to create a dedicated OSD suite that will be used exclusively for fixed dose combination products. The new suite is designed for turnkey, multi-layer tablet production, equipped with advanced capabilities and technology to support granulation, compression, tableting, and coating. This suite will facilitate the production of NewAmsterdam Pharma's investigational FDC, a non-statin cholesterol medication to reduce LDL-C. Although the suite is essential to the FDC's production, the partnership between Piramal Pharma Solutions and NewAmsterdam Pharma extends beyond the Sellersville site. Piramal's Ahmedabad PPDS, India site played a crucial role in the product's development, while its Pithampur, India site provides dual sourcing support. "We are thrilled to expand our OSD production capabilities at the Sellersville facility with this new manufacturing suite," said Peter DeYoung, CEO, Piramal Global Pharma. "This addition will not only enhance our production capacity and speed, but reinforce our commitment to patient centricity, too." "By investing in Piramal Pharma Solutions' Sellersville facility, we are enabling the manufacture of FDC with exceptional precision and efficiency to meet the future commercial demand," said Douglas Kling, COO, NewAmsterdam Pharma. "We are excited to continue growing alongside our trusted partner, Piramal Pharma Solutions, and thrilled about the potential for our collaboration to benefit countless patients around the globe." Patients aren't the only beneficiaries of this investment. Over the next five years, the suite is expected to create more than 20 new jobs at the Sellersville site, further contributing to the local economy and workforce. This investment underscores the commitment to continuous improvement shared by Piramal Pharma Solutions and NewAmsterdam Pharma. By adding the new production suite, both companies can operate with greater efficiency and capacity, ultimately bringing the FDC product, if approved, to more patients in need. About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. The Company seeks to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit: Piramal Pharma Solutions | LinkedIn| Facebook | X About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. For more information, visit: Piramal Pharma | LinkedIn * Includes one facility via PPL's minority investment in Yapan Bio. Photo : : : : : View original content to download multimedia: SOURCE Piramal Pharma Solutions View original content to download multimedia:

Centerbridge's cofounder says Wall Street is missing great hires
Centerbridge's cofounder says Wall Street is missing great hires

Business Insider

time10 minutes ago

  • Business Insider

Centerbridge's cofounder says Wall Street is missing great hires

Wall Street's best hires don't look anything like the résumés it worships, said Jeff Aronson, a cofounder of Centerbridge Partners, a private equity firm managing more than $42 billion in assets. "I joke with people I couldn't get a job at my own firm," Aronson said in the Goldman Sachs "Exchanges" podcast on July 16. "I didn't go to an Ivy League school. I didn't graduate Phi Beta Kappa. I don't speak six languages. I didn't discover the cure for cancer when I was nine years old," he said in the recording uploaded on Tuesday. Aronson came up through Johns Hopkins, where he earned a BA with honors, and NYU School of Law, a path outside the Ivy League track that dominates Wall Street recruiting. US News and World Report ranks Baltimore-based Johns Hopkins sixth on its top national universities list. Wall Street is often stereotyped as an Ivy League stronghold. But data from Revelio Labs showed that only 11.7% of New York-based front-office workers at top firms — including JPMorgan Chase, Goldman Sachs, Morgan Stanley, and Citigroup — graduated from Ivy-plus schools, defined as the Ivy League plus Chicago, Stanford, Duke, and MIT. For Aronson, credentials aren't what make someone a great investor. What matters is mindset, he said. "Attributes, it's the same thing that you folks look for: people who are smart and hardworking and driven," he said. But he also prizes people who are "really intellectually curious." That's partly why he believes Wall Street keeps overlooking promising talent. "So we're all scrambling and tripping over ourselves, looking for the same people," Aronson said. But the real edge comes from hiring those who think independently, he said. He recalled asking candidates whether they compared notes with friends on the buy side — a question he phrased to encourage a "yes." But what he actually wanted to hear was a "no" — because he wanted people who would do their own work, and make their own decisions. That contrarian streak has also shaped where he looks for talent. Rather than only competing for the same Ivy League graduates as every other firm, Aronson also turned his attention to the City University of New York. With over 240,000 degree-program students, CUNY is the largest public urban university in the US, but one that few Wall Street recruiters seriously consider. "I met some of these kids, and they were smart and they were hardworking. But you know what else they had? They had grit. There was no millennial stuff," he said. "Zero. They had grit. Most of them worked their way through school. And so we started hiring them. And all they wanted — it reminded me a little like when I started. 'I just want a chance. Give me a chance,'" Aronson said. "And we started hiring these kids, and they were great," he said. Calling CUNY "the undiscovered jewel that no one's thinking about," Aronson has partnered with John Waldron, president of Goldman, and billionaire Mike Bloomberg to invest millions into programs linking its students with finance jobs. The initiative, he added, has been a win for everyone involved: "It's been a huge win for these students. It's been great for New York City. And it's been smart business."

Target's CEO is stepping down as customers turn away
Target's CEO is stepping down as customers turn away

Yahoo

time16 minutes ago

  • Yahoo

Target's CEO is stepping down as customers turn away

Target CEO Brian Cornell is stepping down after 11 years at the retailer, as the company faces slumping sales and backlash to its retreat on DEI. Cornell's departure was widely expected. Some industry analysts believed Target should bring in an outside voice to lead the company, but it opted for an internal candidate: Cornell will be replaced on February 1, 2026, by Michael Fiddelke, Target's current chief operating officer. Fiddelke started as an intern at Target and has been at the company for 20 years. Fiddelke was chosen from a 'strong list of external and internal candidates,' Cornell said on a call with analysts Wednesday, adding that he is the 'right candidate to lead our business back to growth.' Cornell will stay on as executive chairman. He took over in 2014 and revitalized Target, overseeing a strategy to remodel stores and strengthen the chain's online business to compete with Amazon. But Target has been in a deep slump for years, a result largely of its own strategic missteps. The company has struggled as customers have purchased less of its home goods and clothing. Target has also faced intense competition from Walmart, Amazon and Costco. Target on Wednesday reported sales fell for the third-straight quarter. Shares fell 10% in premarket trading. Target's (TGT) stock is among the worst performing companies in the S&P 500 this year. Target's stock drop reflects many investors' belief that the chain needed to go in a new direction with its choice of CEO. Some analysts criticized Target's board for choosing an insider who has helped develop Target's current strategy. 'This an internal appointment that does not necessarily remedy the problems of entrenched groupthink and the inward-looking mindset that have plagued Target for years,' Neil Saunders, an analyst at GlobalData Retail, said in a note to clients Wednesday. 'Target, which used to be very attuned to consumer demand, has lost its grip on delivering for the American shopper.' DEI retreat and shopper slowdown The last three years have been unkind to target, but 2025 has been particularly tumultuous. Earlier this year, the company ended some of its DEI programs. The decision angered supporters of diversity and inclusion policies, who felt blindsided by Target. Customers online protested Target's decision, and Anne and Lucy Dayton, the daughters of one of Target's co-founders, called the company's actions 'a betrayal.' Target acknowledged its move hurt its sales. 'People re-evaluated and started driving extra miles to go to other places,' Rev. Jamal Bryant, who led a boycott against Target, told CNN. 'We felt like it was a stark betrayal.' Target wasn't the only company to roll back DEI policies, but came under more pressure because it had more deeply ingrained diversity and inclusion programs into the core of its business. Target also has a more progressive base of customers than many competitors. Tariffs and a consumer slowdown have put even more pressure on Target. Target is known for its trendier items, and the chain stocks more nonessential merchandise than its competitors. More than half of Target's merchandise is discretionary. But that merchandise has slumped as shoppers spend more on essentials such as food and household basics. Around half of Walmart's business, for example, comes from groceries. Target also imports about half of its merchandise, compared to roughly 33% at Walmart, so it needs to raise prices at almost double the rate of Walmart to mitigate the tariff impact, Bank of America analyst Robert Ohmes said in a report this week. Rocky tenure Target's recent struggles are a reversal of Cornell's early years at the retailer. In 2018, Target reported its best results in a decade. The following year, Cornell was named CNN Business' CEO of the Year for leading a turnaround at Target. The company thrived at a time when many brick-and-mortar stores were closing. 'Target has earned a place in the retail winners' circle by investing in our business and staying true to our guests and our purpose,' Cornell told CNN in 2019. Target also boomed during the pandemic in 2020 and 2021 as shoppers rushed to stores to purchase essentials, home goods, office supplies and other merchandise. The company's home goods also proved popular as stuck-at-home Americans looked to improve their living spaces when they couldn't venture outside. But Target began to falter in 2022. The chain bought too much merchandise, so it had to deal with a glut of unsold inventory just as decades-high inflation pressured the wallets of many of its shoppers. Post-pandemic, shoppers stopped buying up treadmills, TVs and home goods – especially as inflation started to bite. A year later, activists and customers on the right attacked Target on social media for its LGBTQ-themed merchandise during Pride Month. Target employees faced threats over items such as bathing suits designed for transgender people, and the company removed them from stores. Misinformation spread on social media that the swimsuits were marketed to children, which they were not. The backlash led to a drop in sales and lawsuits from Republican-aligned legal groups. 'We must improve' Fiddelke said Target 'must improve' and the company is 'not realizing our full potential right now' on a call with analysts Wednesday. He outlined a plan to bring trendier merchandise to Target, make its stores more appealing to visit and to invest in technology. This includes an initiative called 'Fun 101,' which seeks to capitalize on the latest trends for electronics and home goods. The company has been able to navigate tariffs so far, he said, and will raise prices as a last resort. Target has changed some of its merchandise selection to mitigate the impact of tariffs. Analysts are mixed as to whether Target's issues are easily solvable or if drastic changes are necessary to revive to the business. 'Target's long-term outlook is deteriorating,' Ohmes said. 'Target is falling behind peers and has tougher challenges.' CNN's Ryan Young contributed to this article. This story has been updated with additional developments and context.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store